Municipal Employees Retirement System of Michigan bought a new position in BIO-TECHNE Corp (NASDAQ:TECH) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 9,070 shares of the biotechnology company’s stock, valued at approximately $1,313,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC raised its stake in BIO-TECHNE by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 416,496 shares of the biotechnology company’s stock valued at $60,275,000 after buying an additional 27,587 shares during the last quarter. Chiron Investment Management LLC raised its stake in BIO-TECHNE by 91.3% during the fourth quarter. Chiron Investment Management LLC now owns 1,467 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 700 shares during the last quarter. Macquarie Group Ltd. raised its stake in BIO-TECHNE by 2.5% during the third quarter. Macquarie Group Ltd. now owns 179,674 shares of the biotechnology company’s stock valued at $36,673,000 after buying an additional 4,398 shares during the last quarter. Stevens Capital Management LP purchased a new position in shares of BIO-TECHNE in the third quarter worth $2,883,000. Finally, FMR LLC purchased a new position in shares of BIO-TECHNE in the third quarter worth $225,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
NASDAQ:TECH traded down $0.88 during mid-day trading on Monday, hitting $200.62. 101,700 shares of the company traded hands, compared to its average volume of 198,113. BIO-TECHNE Corp has a one year low of $132.75 and a one year high of $206.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.31 and a current ratio of 4.35. The firm has a market capitalization of $7.64 billion, a PE ratio of 49.29, a P/E/G ratio of 4.57 and a beta of 1.25.
TECH has been the subject of several recent analyst reports. Argus restated a “buy” rating on shares of BIO-TECHNE in a research note on Monday, March 4th. BidaskClub raised BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Craig Hallum reaffirmed a “hold” rating and issued a $179.00 price objective (up previously from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. Zacks Investment Research raised BIO-TECHNE from a “sell” rating to a “hold” rating in a report on Saturday, January 5th. Finally, Stephens raised BIO-TECHNE from an “equal weight” rating to an “overweight” rating and set a $180.00 price objective for the company in a report on Monday, January 14th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $188.13.
COPYRIGHT VIOLATION WARNING: “Municipal Employees Retirement System of Michigan Acquires New Holdings in BIO-TECHNE Corp (NASDAQ:TECH)” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/15/municipal-employees-retirement-system-of-michigan-buys-shares-of-9070-bio-techne-corp-tech.html.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Read More: What is the NASDAQ?
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.